Korro Bio, Inc. $KRRO Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC grew its stake in Korro Bio, Inc. (NASDAQ:KRRO) by 81.9% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 136,227 shares of the company’s stock after acquiring an additional 61,327 shares during the period. Renaissance Technologies LLC owned about 0.94% of Korro Bio worth $1,542,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in KRRO. Algert Global LLC acquired a new stake in shares of Korro Bio during the third quarter worth $340,000. Alliancebernstein L.P. bought a new position in Korro Bio during the third quarter worth about $369,000. Schonfeld Strategic Advisors LLC acquired a new stake in Korro Bio in the 3rd quarter worth about $4,319,000. Raymond James Financial Inc. raised its stake in Korro Bio by 78.6% in the 3rd quarter. Raymond James Financial Inc. now owns 148,971 shares of the company’s stock worth $7,134,000 after purchasing an additional 65,579 shares in the last quarter. Finally, Two Sigma Investments LP boosted its holdings in Korro Bio by 75.4% in the 3rd quarter. Two Sigma Investments LP now owns 64,455 shares of the company’s stock valued at $3,087,000 after purchasing an additional 27,709 shares during the period. 13.18% of the stock is currently owned by institutional investors and hedge funds.

Korro Bio News Summary

Here are the key news stories impacting Korro Bio this week:

• Positive Sentiment: HC Wainwright raised its earnings forecasts across 2026 and 2027. The firm now expects a smaller loss of $4.88 per share for fiscal 2026, compared with its prior estimate of $5.81, and a $5.04 loss for fiscal 2027 versus its previous forecast of $6.23. Quarterly estimates were also revised to show narrower losses. The analyst maintained a Buy rating and a $15 price target, indicating potential upside from recent trading levels. Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Halozyme (HALO) and Resmed (RMD)
• Neutral Sentiment: Short-interest data provides no meaningful signal. A report listed short interest at zero shares as of August 11, unchanged from the prior period, with a zero-day days-to-cover ratio. However, the reported percentage change was shown as “NaN,” suggesting a data or reporting issue rather than a substantive change in investor positioning.

Wall Street Analyst Weigh In

KRRO has been the topic of several recent research reports. HC Wainwright lowered their target price on shares of Korro Bio from $20.00 to $15.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Wall Street Zen upgraded Korro Bio from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. JonesTrading upgraded Korro Bio from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. Lifesci Capital raised Korro Bio to a “strong-buy” rating in a report on Friday, May 29th. Finally, Citigroup initiated coverage on Korro Bio in a report on Monday, May 18th. They set a “buy” rating and a $21.00 target price on the stock. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $16.71.

Korro Bio Price Performance

NASDAQ KRRO opened at $13.35 on Thursday. The business has a fifty day moving average price of $12.30 and a two-hundred day moving average price of $12.16. Korro Bio, Inc. has a fifty-two week low of $5.20 and a fifty-two week high of $55.89. The stock has a market capitalization of $196.65 million, a PE ratio of -1.33 and a beta of 3.04.

Korro Bio (NASDAQ:KRRO) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.34) by $0.27. Korro Bio had a negative return on equity of 114.26% and a negative net margin of 1,834.48%.The company had revenue of $1.50 million for the quarter, compared to analyst estimates of $0.21 million. As a group, sell-side analysts expect that Korro Bio, Inc. will post -4.97 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Ram Aiyar sold 15,152 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $12.98, for a total value of $196,672.96. Following the completion of the transaction, the chief executive officer owned 74,848 shares of the company’s stock, valued at approximately $971,527.04. This represents a 16.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jean Francois Formela sold 119,005 shares of the firm’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $14.25, for a total transaction of $1,695,821.25. Following the completion of the sale, the director owned 176,649 shares in the company, valued at approximately $2,517,248.25. The trade was a 40.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 306,026 shares of company stock worth $4,309,637 in the last ninety days. Insiders own 4.80% of the company’s stock.

Korro Bio Profile

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.